Does the media favor MBX or CYTK?

In the previous week, MBX Biosciences had 1 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for MBX Biosciences and 10 mentions for Cytokinetics. MBX Biosciences' average media sentiment score of 1.02 beat Cytokinetics' score of 0.43 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer MBX or IBRX?

In the previous week, MBX Biosciences had 2 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for MBX Biosciences and 9 mentions for ImmunityBio. MBX Biosciences' average media sentiment score of 1.02 beat ImmunityBio's score of 0.32 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, NUVL or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A MBX Biosciences N/A N/A -$86.97M -$2.21 N/A

Is NUVL or MBX more profitable?

MBX Biosciences' return on equity of -24.52% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% MBX Biosciences N/A -24.52% -23.59%

Does the media refer more to NUVL or MBX?

In the previous week, Nuvalent and Nuvalent both had 11 articles in the media. MBX Biosciences' average media sentiment score of 1.02 beat Nuvalent's score of 0.52 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KYMR or MBX?

In the previous week, MBX Biosciences had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for MBX Biosciences and 10 mentions for Kymera Therapeutics. MBX Biosciences' average media sentiment score of 1.02 beat Kymera Therapeutics' score of 0.50 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MBX or PRAX more profitable?

MBX Biosciences' return on equity of -24.52% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media refer more to MBX or PRAX?

In the previous week, MBX Biosciences had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 11 mentions for MBX Biosciences and 6 mentions for Praxis Precision Medicines. MBX Biosciences' average media sentiment score of 1.02 beat Praxis Precision Medicines' score of 0.75 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MBX Biosciences (MBX) Competitors

$59.97 -1.08 (-1.77%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$57.54 -2.43 (-4.05%)

As of 05:28 AM Eastern

Compare

MBX vs. CYTK, IBRX, NUVL, KYMR, and PRAX

Should you buy MBX Biosciences stock or one of its competitors? MarketBeat compares MBX Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MBX Biosciences include Cytokinetics (CYTK), ImmunityBio (IBRX), Nuvalent (NUVL), Kymera Therapeutics (KYMR), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does MBX Biosciences compare to Cytokinetics?

MBX Biosciences (NASDAQ:MBX) and Cytokinetics (NASDAQ:CYTK) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

MBX Biosciences has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, MBX Biosciences had 1 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for MBX Biosciences and 10 mentions for Cytokinetics. MBX Biosciences' average media sentiment score of 1.02 beat Cytokinetics' score of 0.43 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

MBX Biosciences has higher earnings, but lower revenue than Cytokinetics. MBX Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

MBX Biosciences has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Cytokinetics	-784.02%	N/A	-52.86%

MBX Biosciences presently has a consensus price target of $60.22, indicating a potential upside of 0.42%. Cytokinetics has a consensus price target of $99.90, indicating a potential upside of 21.47%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Cytokinetics beats MBX Biosciences on 8 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to ImmunityBio?

MBX Biosciences (NASDAQ:MBX) and ImmunityBio (NASDAQ:IBRX) are both mid-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

8.6% of ImmunityBio shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MBX Biosciences has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
ImmunityBio	-606.15%	N/A	-59.53%

MBX Biosciences has higher earnings, but lower revenue than ImmunityBio. MBX Biosciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
ImmunityBio	$113.29M	72.02	-$351.40M	-$0.85	N/A

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 0.42%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 82.28%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MBX Biosciences has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

In the previous week, MBX Biosciences had 2 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for MBX Biosciences and 9 mentions for ImmunityBio. MBX Biosciences' average media sentiment score of 1.02 beat ImmunityBio's score of 0.32 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MBX Biosciences beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and MBX Biosciences (NASDAQ:MBX) are both mid-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

97.3% of Nuvalent shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MBX Biosciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

MBX Biosciences' return on equity of -24.52% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
MBX Biosciences	N/A	-24.52%	-23.59%

Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

In the previous week, Nuvalent and Nuvalent both had 11 articles in the media. MBX Biosciences' average media sentiment score of 1.02 beat Nuvalent's score of 0.52 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent currently has a consensus target price of $127.73, suggesting a potential upside of 3.06%. MBX Biosciences has a consensus target price of $60.22, suggesting a potential upside of 0.42%. Given Nuvalent's higher possible upside, research analysts clearly believe Nuvalent is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

MBX Biosciences beats Nuvalent on 9 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and MBX Biosciences (NASDAQ:MBX) are both mid-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

MBX Biosciences has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	231.61	-$311.35M	-$3.57	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

In the previous week, MBX Biosciences had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for MBX Biosciences and 10 mentions for Kymera Therapeutics. MBX Biosciences' average media sentiment score of 1.02 beat Kymera Therapeutics' score of 0.50 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. MBX Biosciences' return on equity of -24.52% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
MBX Biosciences	N/A	-24.52%	-23.59%

Kymera Therapeutics presently has a consensus target price of $121.73, indicating a potential upside of 10.26%. MBX Biosciences has a consensus target price of $60.22, indicating a potential upside of 0.42%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kymera Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.91
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

MBX Biosciences beats Kymera Therapeutics on 7 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Praxis Precision Medicines?

MBX Biosciences (NASDAQ:MBX) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, MBX Biosciences had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 11 mentions for MBX Biosciences and 6 mentions for Praxis Precision Medicines. MBX Biosciences' average media sentiment score of 1.02 beat Praxis Precision Medicines' score of 0.75 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MBX Biosciences has higher earnings, but lower revenue than Praxis Precision Medicines. MBX Biosciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Praxis Precision Medicines	$8.55M	1,025.72	-$303.27M	-$13.37	N/A

MBX Biosciences has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 0.42%. Praxis Precision Medicines has a consensus target price of $563.50, suggesting a potential upside of 79.14%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

MBX Biosciences' return on equity of -24.52% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Summary

Praxis Precision Medicines beats MBX Biosciences on 8 of the 15 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.91B	$931.69M	$5.06B	$12.61B
Dividend Yield	N/A	4.84%	27.48%	8.00%
P/E Ratio	-27.14	1.56	23.70	24.26
Price / Sales	N/A	114.76	146.11	117.88
Price / Cash	N/A	22.05	31.98	49.36
Price / Book	7.30	8.59	12.23	6.29
Net Income	-$86.97M	-$3.66M	$118.20M	$330.66M
7 Day Performance	-3.27%	-2.06%	-1.63%	-1.35%
1 Month Performance	68.88%	0.77%	-1.93%	-0.64%
1 Year Performance	N/A	37.84%	8.97%	19.08%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	1.1321 of 5 stars	$59.97 -1.8%	$60.22 +0.4%	N/A	$2.91B	N/A	N/A	N/A	News Coverage Positive News Analyst Upgrade
CYTK Cytokinetics	2.4789 of 5 stars	$86.49 flat	$100.00 +15.6%	+122.2%	$10.76B	$88.04M	N/A	250
IBRX ImmunityBio	2.9886 of 5 stars	$9.44 flat	$14.20 +50.4%	+177.2%	$9.89B	$113.29M	N/A	590	Gap Down
NUVL Nuvalent	2.2876 of 5 stars	$123.73 flat	$127.73 +3.2%	+53.1%	$9.77B	N/A	N/A	40
KYMR Kymera Therapeutics	1.8936 of 5 stars	$113.51 flat	$121.41 +7.0%	+148.2%	$9.34B	$39.21M	N/A	170	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. CYTK, IBRX, NUVL, KYMR, and PRAX

How does MBX Biosciences compare to Cytokinetics?

Summary

How does MBX Biosciences compare to ImmunityBio?

Summary

How does MBX Biosciences compare to Nuvalent?

Summary

How does MBX Biosciences compare to Kymera Therapeutics?

Summary

How does MBX Biosciences compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. CYTK, IBRX, NUVL, KYMR, and PRAX

How does MBX Biosciences compare to Cytokinetics?

Which has more volatility & risk, MBX or CYTK?

Does the media favor MBX or CYTK?

Which has preferable earnings & valuation, MBX or CYTK?

Is MBX or CYTK more profitable?

Do analysts rate MBX or CYTK?

Summary

How does MBX Biosciences compare to ImmunityBio?

Do institutionals & insiders hold more shares of MBX or IBRX?

Is MBX or IBRX more profitable?

Which has higher valuation & earnings, MBX or IBRX?

Do analysts rate MBX or IBRX?

Which has more volatility and risk, MBX or IBRX?

Does the media prefer MBX or IBRX?

Summary

How does MBX Biosciences compare to Nuvalent?

Do insiders and institutionals have more ownership in NUVL or MBX?

Which has higher valuation and earnings, NUVL or MBX?

Is NUVL or MBX more profitable?

Which has more risk and volatility, NUVL or MBX?

Does the media refer more to NUVL or MBX?

Do analysts recommend NUVL or MBX?

Summary

How does MBX Biosciences compare to Kymera Therapeutics?

Which has more risk & volatility, KYMR or MBX?

Which has preferable valuation and earnings, KYMR or MBX?

Does the media favor KYMR or MBX?

Is KYMR or MBX more profitable?

Do analysts rate KYMR or MBX?

Summary

How does MBX Biosciences compare to Praxis Precision Medicines?

Does the media refer more to MBX or PRAX?

Do insiders & institutionals hold more shares of MBX or PRAX?

Which has higher earnings and valuation, MBX or PRAX?

Which has more risk and volatility, MBX or PRAX?

Do analysts prefer MBX or PRAX?

Is MBX or PRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools